Unless otherwise specified, data provided are specific to the fludarabine-refractory patients; the number of fludarabine-refractory patients in each study is listed in the left column.

*Number of fludarabine-refractory patients of the total reported to date; data are for entire relapsed/refractory study population.

SC indicates subcutaneous; NR, not reported; FFS, failure-free survival; TTF, time to treatment failure; TTP, time to progression; DOR, duration of remission.